WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018015958) AR ANTAGONISTS OR INHIBITORS FOR USE IN TREATING GLIOBLASTOMA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/015958 International Application No.: PCT/IL2017/050819
Publication Date: 25.01.2018 International Filing Date: 20.07.2017
IPC:
A61K 31/4166 (2006.01) ,A61K 31/00 (2006.01) ,A61K 45/06 (2006.01) ,A61K 31/175 (2006.01) ,A61K 31/495 (2006.01) ,A61K 31/517 (2006.01) ,G01N 33/50 (2006.01) ,A61P 35/00 (2006.01)
Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.[IL/IL]; P.O. Box 12000 9112001 Jerusalem, IL
Inventors: LAVON BEN MOSHE, Iris; IL
CANELLO AVRAMOVITCH, Tamar; IL
Agent: WEBB, Cynthia; IL
WEBB, Cynthia; IL
BARZAM, Maty; IL
BOGIN, Liora; IL
BURSTEIN, Tal; IL
FINAROV, Igal; IL
GANOR, Sharon; IL
HORNIK, Vered; IL
NOAH, Eran; IL
POTASH, Shay; IL
SCHICKLER, Hedva; IL
SCHVARTZ, Iris; IL
SILVERMAN, Eran; IL
TRAVITSKY, Nina; IL
WEBB, Yael; IL
ZIPOR, Gadi; IL
Priority Data:
62/364,87421.07.2016US
62/419,98110.11.2016US
Title (EN) AR ANTAGONISTS OR INHIBITORS FOR USE IN TREATING GLIOBLASTOMA
(FR) ANTAGONISTES OU INHIBITEURS D’AR POUR UTILISATION DANS LE TRAITEMENT DU GLIOBLASTOME
Abstract:
(EN) The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
(FR) La présente invention concerne le traitement de tumeurs cérébrales, spécifiquement une thérapie améliorée pour le glioblastome au moyen de modulateurs et de combinaisons de médicaments endocriniens spécifiques. Les compositions et les utilisations de celles-ci selon l’invention utilisent des inhibiteurs de récepteur d’androgène (AR), seuls ou en combinaison avec des inhibiteurs de récepteur tyrosine kinase et/ou des agents chimiothérapeutiques. Selon certains modes de réalisation avantageux, l’invention concerne l’utilisation de l’inhibiteur d’AR enzalutamide, éventuellement en combinaison avec des inhibiteurs du récepteur du facteur de croissance épidermique tels que l’erlotinib et des agents d’alkylation tels que la carmustine et le témozolomide.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Licensing availability request The applicant has requested the International Bureau to indicate the availability for licensing purposes of the invention(s) claimed in this international application